Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS

J. A. Cohen, P. B. Imrey, Peter Calabresi, K. R. Edwards, T. Eickenhorst, W. L. Felton, E. Fisher, R. J. Fox, A. D. Goodman, C. Hara-Cleaver, G. J. Hutton, B. F. Mandell, T. F. Scott, H. Zhang, C. Apperson-Hansen, G. J. Beck, P. L. Houghtaling, M. T. Karafa, M. Stadtler

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: To assess the safety, tolerability, and efficacy of interferon beta-1a (IFNβ-1a) combined with methotrexate (MTX), IV methylprednisolone (IVMP), or both in patients with relapsing-remitting multiple sclerosis (RRMS) with continued disease activity on IFNβ-1a monotherapy. METHODS: Eligibility criteria included RRMS, Expanded Disability Status Scale score 0-5.5, and ≥1 relapse or gadolinium-enhancing MRI lesion in the prior year on IFNβ-1a monotherapy. Participants continued weekly IFNβ-1a 30 μg IM and were randomized in a 2 × 2 factorial design to adjunctive weekly placebo or MTX 20 mg PO, with or without bimonthly IVMP 1,000 mg/day for 3 days. The primary endpoint was new or enlarged T2 lesion number at month 12 vs baseline. The study was industry-supported, collaboratively designed, and governed by an investigator Steering Committee with independent Advisory and Data Safety Monitoring committees. Study operations, MRI analyses, and aggregated data were managed by an academic coordinating center. RESULTS: The 313 participants had clinical and MRI characteristics typical of RRMS. Combinations of IFNβ-1a with MTX or IVMP were generally safe and well tolerated. Although trends suggesting modest benefit were seen for some outcomes for IVMP, the results did not demonstrate significant benefit for either adjunctive therapy. The data suggested IVMP reduced anti-IFNβ neutralizing antibody titers. CONCLUSIONS: This trial did not demonstrate benefit of adding low-dose oral methotrexate or every other month IV methylprednisolone to interferon beta-1a in relapsing-remitting multiple sclerosis.

Original languageEnglish (US)
Pages (from-to)535-541
Number of pages7
JournalNeurology
Volume72
Issue number6
DOIs
StatePublished - Feb 10 2009

Fingerprint

Methylprednisolone
Relapsing-Remitting Multiple Sclerosis
Methotrexate
Clinical Trials Data Monitoring Committees
Safety
Gadolinium
Neutralizing Antibodies
Interferon beta-1a
Industry
Placebos
Research Personnel
Recurrence

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Cohen, J. A., Imrey, P. B., Calabresi, P., Edwards, K. R., Eickenhorst, T., Felton, W. L., ... Stadtler, M. (2009). Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS. Neurology, 72(6), 535-541. https://doi.org/10.1212/01.wnl.0000341934.12142.74

Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS. / Cohen, J. A.; Imrey, P. B.; Calabresi, Peter; Edwards, K. R.; Eickenhorst, T.; Felton, W. L.; Fisher, E.; Fox, R. J.; Goodman, A. D.; Hara-Cleaver, C.; Hutton, G. J.; Mandell, B. F.; Scott, T. F.; Zhang, H.; Apperson-Hansen, C.; Beck, G. J.; Houghtaling, P. L.; Karafa, M. T.; Stadtler, M.

In: Neurology, Vol. 72, No. 6, 10.02.2009, p. 535-541.

Research output: Contribution to journalArticle

Cohen, JA, Imrey, PB, Calabresi, P, Edwards, KR, Eickenhorst, T, Felton, WL, Fisher, E, Fox, RJ, Goodman, AD, Hara-Cleaver, C, Hutton, GJ, Mandell, BF, Scott, TF, Zhang, H, Apperson-Hansen, C, Beck, GJ, Houghtaling, PL, Karafa, MT & Stadtler, M 2009, 'Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS', Neurology, vol. 72, no. 6, pp. 535-541. https://doi.org/10.1212/01.wnl.0000341934.12142.74
Cohen, J. A. ; Imrey, P. B. ; Calabresi, Peter ; Edwards, K. R. ; Eickenhorst, T. ; Felton, W. L. ; Fisher, E. ; Fox, R. J. ; Goodman, A. D. ; Hara-Cleaver, C. ; Hutton, G. J. ; Mandell, B. F. ; Scott, T. F. ; Zhang, H. ; Apperson-Hansen, C. ; Beck, G. J. ; Houghtaling, P. L. ; Karafa, M. T. ; Stadtler, M. / Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS. In: Neurology. 2009 ; Vol. 72, No. 6. pp. 535-541.
@article{5cf7840442474b6ea38c6d3c9aa88107,
title = "Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS",
abstract = "OBJECTIVE: To assess the safety, tolerability, and efficacy of interferon beta-1a (IFNβ-1a) combined with methotrexate (MTX), IV methylprednisolone (IVMP), or both in patients with relapsing-remitting multiple sclerosis (RRMS) with continued disease activity on IFNβ-1a monotherapy. METHODS: Eligibility criteria included RRMS, Expanded Disability Status Scale score 0-5.5, and ≥1 relapse or gadolinium-enhancing MRI lesion in the prior year on IFNβ-1a monotherapy. Participants continued weekly IFNβ-1a 30 μg IM and were randomized in a 2 × 2 factorial design to adjunctive weekly placebo or MTX 20 mg PO, with or without bimonthly IVMP 1,000 mg/day for 3 days. The primary endpoint was new or enlarged T2 lesion number at month 12 vs baseline. The study was industry-supported, collaboratively designed, and governed by an investigator Steering Committee with independent Advisory and Data Safety Monitoring committees. Study operations, MRI analyses, and aggregated data were managed by an academic coordinating center. RESULTS: The 313 participants had clinical and MRI characteristics typical of RRMS. Combinations of IFNβ-1a with MTX or IVMP were generally safe and well tolerated. Although trends suggesting modest benefit were seen for some outcomes for IVMP, the results did not demonstrate significant benefit for either adjunctive therapy. The data suggested IVMP reduced anti-IFNβ neutralizing antibody titers. CONCLUSIONS: This trial did not demonstrate benefit of adding low-dose oral methotrexate or every other month IV methylprednisolone to interferon beta-1a in relapsing-remitting multiple sclerosis.",
author = "Cohen, {J. A.} and Imrey, {P. B.} and Peter Calabresi and Edwards, {K. R.} and T. Eickenhorst and Felton, {W. L.} and E. Fisher and Fox, {R. J.} and Goodman, {A. D.} and C. Hara-Cleaver and Hutton, {G. J.} and Mandell, {B. F.} and Scott, {T. F.} and H. Zhang and C. Apperson-Hansen and Beck, {G. J.} and Houghtaling, {P. L.} and Karafa, {M. T.} and M. Stadtler",
year = "2009",
month = "2",
day = "10",
doi = "10.1212/01.wnl.0000341934.12142.74",
language = "English (US)",
volume = "72",
pages = "535--541",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS

AU - Cohen, J. A.

AU - Imrey, P. B.

AU - Calabresi, Peter

AU - Edwards, K. R.

AU - Eickenhorst, T.

AU - Felton, W. L.

AU - Fisher, E.

AU - Fox, R. J.

AU - Goodman, A. D.

AU - Hara-Cleaver, C.

AU - Hutton, G. J.

AU - Mandell, B. F.

AU - Scott, T. F.

AU - Zhang, H.

AU - Apperson-Hansen, C.

AU - Beck, G. J.

AU - Houghtaling, P. L.

AU - Karafa, M. T.

AU - Stadtler, M.

PY - 2009/2/10

Y1 - 2009/2/10

N2 - OBJECTIVE: To assess the safety, tolerability, and efficacy of interferon beta-1a (IFNβ-1a) combined with methotrexate (MTX), IV methylprednisolone (IVMP), or both in patients with relapsing-remitting multiple sclerosis (RRMS) with continued disease activity on IFNβ-1a monotherapy. METHODS: Eligibility criteria included RRMS, Expanded Disability Status Scale score 0-5.5, and ≥1 relapse or gadolinium-enhancing MRI lesion in the prior year on IFNβ-1a monotherapy. Participants continued weekly IFNβ-1a 30 μg IM and were randomized in a 2 × 2 factorial design to adjunctive weekly placebo or MTX 20 mg PO, with or without bimonthly IVMP 1,000 mg/day for 3 days. The primary endpoint was new or enlarged T2 lesion number at month 12 vs baseline. The study was industry-supported, collaboratively designed, and governed by an investigator Steering Committee with independent Advisory and Data Safety Monitoring committees. Study operations, MRI analyses, and aggregated data were managed by an academic coordinating center. RESULTS: The 313 participants had clinical and MRI characteristics typical of RRMS. Combinations of IFNβ-1a with MTX or IVMP were generally safe and well tolerated. Although trends suggesting modest benefit were seen for some outcomes for IVMP, the results did not demonstrate significant benefit for either adjunctive therapy. The data suggested IVMP reduced anti-IFNβ neutralizing antibody titers. CONCLUSIONS: This trial did not demonstrate benefit of adding low-dose oral methotrexate or every other month IV methylprednisolone to interferon beta-1a in relapsing-remitting multiple sclerosis.

AB - OBJECTIVE: To assess the safety, tolerability, and efficacy of interferon beta-1a (IFNβ-1a) combined with methotrexate (MTX), IV methylprednisolone (IVMP), or both in patients with relapsing-remitting multiple sclerosis (RRMS) with continued disease activity on IFNβ-1a monotherapy. METHODS: Eligibility criteria included RRMS, Expanded Disability Status Scale score 0-5.5, and ≥1 relapse or gadolinium-enhancing MRI lesion in the prior year on IFNβ-1a monotherapy. Participants continued weekly IFNβ-1a 30 μg IM and were randomized in a 2 × 2 factorial design to adjunctive weekly placebo or MTX 20 mg PO, with or without bimonthly IVMP 1,000 mg/day for 3 days. The primary endpoint was new or enlarged T2 lesion number at month 12 vs baseline. The study was industry-supported, collaboratively designed, and governed by an investigator Steering Committee with independent Advisory and Data Safety Monitoring committees. Study operations, MRI analyses, and aggregated data were managed by an academic coordinating center. RESULTS: The 313 participants had clinical and MRI characteristics typical of RRMS. Combinations of IFNβ-1a with MTX or IVMP were generally safe and well tolerated. Although trends suggesting modest benefit were seen for some outcomes for IVMP, the results did not demonstrate significant benefit for either adjunctive therapy. The data suggested IVMP reduced anti-IFNβ neutralizing antibody titers. CONCLUSIONS: This trial did not demonstrate benefit of adding low-dose oral methotrexate or every other month IV methylprednisolone to interferon beta-1a in relapsing-remitting multiple sclerosis.

UR - http://www.scopus.com/inward/record.url?scp=62149143732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62149143732&partnerID=8YFLogxK

U2 - 10.1212/01.wnl.0000341934.12142.74

DO - 10.1212/01.wnl.0000341934.12142.74

M3 - Article

C2 - 19204263

AN - SCOPUS:62149143732

VL - 72

SP - 535

EP - 541

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 6

ER -